KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

TherapeuticsMD (TXMD) Shares Outstanding (Diluted Average): 2022-2025

Historic Shares Outstanding (Diluted Average) for TherapeuticsMD (TXMD) over the last 4 years, with Sep 2025 value amounting to $11.6 million.

  • TherapeuticsMD's Shares Outstanding (Diluted Average) rose 0.36% to $11.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $11.6 million, marking a year-over-year increase of 0.36%. This contributed to the annual value of $11,532 for FY2024, which is 10.45% up from last year.
  • TherapeuticsMD's Shares Outstanding (Diluted Average) amounted to $11.6 million in Q3 2025, which was down 0.00% from $11.6 million recorded in Q2 2025.
  • Over the past 5 years, TherapeuticsMD's Shares Outstanding (Diluted Average) peaked at $11.6 million during Q2 2025, and registered a low of $10,441 during Q4 2023.
  • Its 3-year average for Shares Outstanding (Diluted Average) is $9.1 million, with a median of $11.5 million in 2024.
  • As far as peak fluctuations go, TherapeuticsMD's Shares Outstanding (Diluted Average) crashed by 99.89% in 2023, and later increased by 18.23% in 2024.
  • Over the past 4 years, TherapeuticsMD's Shares Outstanding (Diluted Average) (Quarterly) stood at $9.4 million in 2022, then crashed by 99.89% to $10,441 in 2023, then climbed by 10.45% to $11,532 in 2024, then increased by 0.36% to $11.6 million in 2025.
  • Its last three reported values are $11.6 million in Q3 2025, $11.6 million for Q2 2025, and $11.6 million during Q1 2025.